United States Patent 7,776,314: Claim Scope, Expiration, Litigation Risk and Abuse-Deterrent Dosage-Form Landscape

U.S. Patent No. 7,776,314 covers an oral solid dosage form containing an abuse-prone active ingredient and at least 5 mg of a viscosity-increasing agent. Its central limitation is a functional injection-deterrence test: an aqueous extract made with 10 mL of water at 25°C must form a visually distinguishable gel that remains capable of passing through a 0.9 mm needle.

The patent is a formulation patent, not an active-ingredient patent. It does not claim oxycodone, hydrocodone, morphine, fentanyl or another opioid as such. Its commercial relevance depends on whether a competing product practices the claimed gel-forming formulation and whether the patent remained enforceable during the relevant period. The patent’s base 20-year term has ended, subject to any patent-term adjustment shown in the official patent record. It should not present a current U.S. blocking position in 2025.

What patents protect the formulation claimed in U.S. Patent 7,776,314?

The patent protects a broad class of oral solid dosage forms designed to make parenteral abuse more difficult.

Feature	Claim requirement
Dosage form	Solid dosage form for oral administration
Abuse-prone active	Opiate, opioid, tranquillizer, stimulant or narcotic
Viscosity agent	At least one viscosity-increasing agent
Minimum quantity	At least 5 mg per dosage form or administration unit
Extraction test	Aqueous extraction with 10 mL of water at 25°C
Gel result	The extract forms a gel
Needle condition	The gel can still pass through a 0.9 mm needle
Visual condition	The gel remains visually distinguishable when introduced into another aqueous liquid
Open-ended scope	The term “comprising” permits additional ingredients and processing steps

The independent claim does not require a particular opioid, dosage strength, release profile, excipient concentration, tablet architecture or manufacturing process. It is therefore a platform formulation claim.

The claim is unusual because it does not require the gel to block a needle completely. The gel must remain capable of passing through a 0.9 mm needle while retaining visual distinguishability after injection into another liquid. The claimed mechanism is deterrence and detection rather than absolute physical prevention.

How should claim 1 of U.S. Patent 7,776,314 be construed?

Claim 1 contains five principal limitations.

1. “Parenteral abuse-proofed”

This phrase supplies the intended technical purpose: the dosage form is designed to resist abuse by extraction and injection. The enforceable scope, however, is driven primarily by the structural and functional limitations that follow. A product does not necessarily infringe merely because it is marketed as abuse-deterrent.

The relevant infringement question is whether the product contains the required viscosity-increasing agent and produces the claimed extraction behavior. Marketing language, FDA abuse-deterrent labeling or a manufacturer’s internal abuse-deterrence testing would be relevant evidence but would not replace the claim limitations.

2. “Solid dosage form for oral administration”

The claim reaches tablets, capsules, granules and other solid oral products. Dependent claims expressly add particulate and multiparticulate forms, including microtablets, microcapsules, micropellets, granules, spheroids, beads and pellets.

A liquid injectable, transdermal system or inherently liquid oral formulation would fall outside the literal scope of this limitation. A solid dosage form packaged in a capsule remains within the claimed category.

3. “One or more active ingredients with potential for abuse”

The claim uses broad categories rather than a closed list. Claim 2 supplies an extensive list of specific compounds, including oxycodone, hydrocodone, morphine, fentanyl, methadone, tramadol, amphetamine, methylphenidate, benzodiazepines and barbiturates.

Claim 1 is not limited to the compounds named in claim 2. A product containing another active ingredient could still raise claim 1 issues if the active ingredient has the required potential for abuse and the remaining limitations are met.

4. “At least one viscosity-increasing agent”

Claim 4 identifies representative materials, including:

Sodium carboxymethylcellulose
Microcrystalline cellulose with sodium carboxymethylcellulose
Polyacrylic acid
Sodium alginate
Pectin
Guar gum
Xanthan gum
Gellan gum
Carrageenan
Galactomannan
Tragacanth
Sodium hyaluronate
Welan gum
Locust bean flour
Modified starches

The list in claim 4 is narrower than the functional language of claim 1. A viscosity agent not named in claim 4 may still be covered by claim 1 if it satisfies the claim’s functional requirements.

5. The extraction and visual-distinguishability test

This is the central limitation. The test requires:

Extracting the dosage form with 10 mL of water.
Performing the extraction at 25°C.
Producing a gel.
Demonstrating that the gel can pass through a needle with a 0.9 mm diameter.
Introducing the gel through the needle into a further aqueous liquid.
Showing that the introduced gel remains visually distinguishable.

The claim does not expressly specify extraction time, agitation method, needle length, injection pressure, visual-observation method, pH, ionic strength or the identity of the further aqueous liquid. Those omissions may create claim-construction and reproducibility disputes.

What do the dependent claims add?

Claim	Added limitation	Commercial effect
2	Extensive list of opioids, narcotics and tranquillizers	Ties specific active ingredients to the platform
3	Amphetamine, norpseudoephedrine and methylphenidate	Covers stimulant products
4	Specific viscosity-increasing agents and commercial excipient grades	Narrows formulation examples
5	Particulate form	Covers particles rather than only unitary tablets
6	At least partly controlled release	Reaches extended-release and other modified-release products
7	Gastric-juice-resistant coating	Covers enteric or gastric-resistant architectures
8	Benzodiazepine tranquillizer	Narrows claim 1 to benzodiazepines
9	At least 5 mg per administration unit	Repeats and clarifies the quantity limitation
10	Multiparticulate form	Covers products containing multiple discrete units
11	Microtablets, microcapsules, micropellets, granules, spheroids, beads or pellets	Identifies specific multiparticulate structures
12	Capsules or press-molded tablets	Covers two common commercial presentations

Claims 5, 10 and 11 are particularly relevant to modern abuse-deterrent products using coated pellets, beads or multiparticulate controlled-release systems. Claim 7 could reach a product that combines abuse deterrence with enteric protection, although the product must still satisfy the gel test in claim 1.

What formulations are protected by U.S. Patent 7,776,314?

The strongest literal targets are solid oral formulations that use a hydrophilic polymer or gum to produce a visible, injectable gel after tampering.

Potentially relevant formulation classes include:

Formulation class	Potential claim relevance
Opioid tablet with sodium carboxymethylcellulose	Directly aligned with claim 4
Controlled-release opioid pellets with xanthan or guar gum	Claims 6, 10 and 11 may apply
Capsule containing viscosity-modified microtablets	Claims 10 to 12 may apply
Benzodiazepine tablet with polyacrylic acid	Claim 8 and claim 4 may apply
Methylphenidate multiparticulate capsule	Claim 3 and claims 10 to 12 may apply
Enteric-coated opioid granules containing a gel-forming polymer	Claims 6, 7 and 10 may apply

The presence of an excipient alone is insufficient. The formulation must satisfy the extraction result. A product can contain sodium carboxymethylcellulose or xanthan gum without meeting the claim if the specified extraction does not form the required visually distinguishable gel.

How strong is the patent estate for U.S. Patent 7,776,314?

The patent is strongest against products that closely reproduce the claimed functional test. It is weaker against products that use a different abuse-deterrence mechanism.

Strengths

Claim 1 is not limited to a single active ingredient.
The “comprising” language permits additional excipients and processing features.
The claim reaches multiple dosage-form architectures.
The functional test can cover excipients not expressly listed in claim 4.
Claims 6 and 7 extend into controlled-release and gastric-resistant products.
Claims 10 to 12 address commercial multiparticulate products.

Vulnerabilities

The claim depends on a functional test with several unspecified parameters.
“Visually distinguishable” may be challenged as subjective or insufficiently defined.
“Can still pass through” a 0.9 mm needle may require a reproducible pressure and equipment standard.
The claim does not state how long the gel must remain distinguishable.
A competing product may use a solidification, mechanical-hardness, aversive-agent or irreversible-matrix mechanism rather than viscosity-induced gelation.
The broad active-ingredient categories may face written-description or enablement challenges for compounds not specifically exemplified.
The term “abuse-proofed” may be treated as a purpose statement rather than an independent technical limitation, depending on claim construction.

The principal validity issues would likely involve enablement, indefiniteness, written description and obviousness. The best noninfringement position would usually focus on failure of the extraction test or on the absence of the claimed gel behavior.

When did U.S. Patent 7,776,314 lose exclusivity?

U.S. Patent 7,776,314 issued on August 17, 2010. The patent derives from an early-2000s filing and is subject to the post-1995 U.S. patent-term framework, under which the ordinary term is 20 years from the relevant nonprovisional filing date, subject to patent-term adjustment and any terminal disclaimer shown in the official record.[1]

The base term has expired. Any patent-term adjustment could have extended the enforceable date beyond the nominal 20-year date, but the patent is no longer a current blocking patent in the United States as of 2025. The controlling expiration date should be taken from the USPTO patent record and the patent’s term-adjustment calculation, rather than inferred solely from the grant date.[1][2]

Event	Date or status
Earliest claimed priority	Early 2000s
U.S. patent grant	August 17, 2010
Patent number	7,776,314
Ordinary statutory term	Twenty years from the applicable U.S. filing basis
Current status	Expired by 2025
Current enforceability	No ongoing ordinary U.S. patent exclusion based on the expired patent

Expiration eliminates infringement liability for post-expiration activity. It does not eliminate potential exposure for conduct occurring before expiration, subject to the applicable limitation periods and litigation posture.

What is the Orange Book status of U.S. Patent 7,776,314?

U.S. Patent 7,776,314 is not properly treated as an Orange Book drug patent merely because it covers an oral dosage form containing an opioid or other controlled substance.

The FDA Orange Book lists patents submitted by an NDA holder for an approved drug product. A broad platform patent covering numerous active ingredients does not automatically appear in the Orange Book. An Orange Book listing would require linkage to a particular approved NDA and the relevant drug product.[3]

The patent is therefore different from product-specific patents covering:

An approved opioid’s formulation
A specific extended-release dosage form
A method of using an approved drug
A particular abuse-deterrent delivery system

No Orange Book consequence should be assumed for a generic applicant unless the patent was actually listed against the reference drug product during the relevant period.

Did U.S. Patent 7,776,314 create Paragraph IV risk?

The patent could have been relevant to an abbreviated new drug application only if it was listed in the Orange Book against the relevant reference product.

A Paragraph IV certification applies to a listed patent. A generic applicant asserting that a listed patent is invalid, unenforceable or not infringed may trigger notice and potential litigation under the Hatch-Waxman framework.[4] A standalone formulation patent with no identified Orange Book listing would not ordinarily create a Paragraph IV barrier.

The practical analysis is:

Question	Assessment
Is the patent an active ingredient patent?	No
Is it inherently tied to one NDA product?	No
Is it automatically Orange Book-listed?	No
Could it support a Paragraph IV filing if listed?	Yes
Does expiration eliminate future Paragraph IV blocking value?	Yes
Could pre-expiration listing have mattered?	Yes, if linked to an approved product

What patent litigation affects U.S. Patent 7,776,314?

The patent’s principal litigation risk would have been a conventional formulation-infringement dispute, not necessarily a Hatch-Waxman case.

A patent owner would need to establish that the accused product:

Is a solid oral dosage form.
Contains an abuse-prone active ingredient.
Contains at least 5 mg of a viscosity-increasing agent.
Produces the required gel under the specified extraction conditions.
Produces a gel that passes through a 0.9 mm needle.
Leaves a visually distinguishable gel in the receiving liquid.

Testing would likely become the central evidentiary issue. Discovery could include formulation records, excipient specifications, development reports, tampering studies, dissolution data, microscopy, rheology, needle-selection protocols and regulatory submissions.

No current commercial litigation risk should be assigned to the patent after expiration. Any historical litigation analysis must distinguish this patent from later Grünenthal, Collegium, Acura, Purdue, Egalet, Elite or other abuse-deterrent formulation patents.

Which companies challenged or competed with this patent estate?

The competitive landscape includes two distinct groups.

Patent owners and abuse-deterrent developers

Grünenthal developed a broad family of abuse-deterrent dosage-form technologies, including patents directed to gel formation, tamper resistance and controlled-release formulations. Other developers pursued different platforms:

Purdue Pharma: physically and chemically abuse-deterrent opioid formulations
Acura Pharmaceuticals: DETERx and related abuse-deterrent technologies
Collegium Pharmaceutical: Xtampza ER and DETERx-based commercial technology
Egalet: Guardian Technology and erosion-resistant dosage forms
King Pharmaceuticals and Pfizer: Embeda-related morphine/naltrexone technology
Elite Pharmaceuticals: abuse-deterrent and controlled-release formulation programs

These estates are not interchangeable. A product can avoid the claims of U.S. 7,776,314 and still infringe a later patent directed to tablet hardness, polymer matrices, sequestered antagonists, aversive agents, coating systems or manufacturing processes.

Generic manufacturers

Generic companies would typically focus on one or more of the following design-around strategies:

Removing or reducing the claimed viscosity agent
Using a different tamper-resistant mechanism
Selecting a polymer that does not produce the claimed gel
Changing the dosage form from multiparticulate to a different architecture
Using a matrix that fragments rather than gels
Demonstrating that the extract does not remain visually distinguishable
Avoiding the named controlled-release or gastric-resistant features

Because claim 1 is open-ended, simply changing the brand name, tablet shape or packaging would not avoid the claim.

What manufacturing and intellectual-property barriers remain?

The patent does not claim a specific manufacturing process. Its manufacturing relevance arises from the need to preserve normal oral performance while creating the claimed extraction behavior.

Technical barriers include:

Uniform distribution of the viscosity agent
Control of polymer hydration
Prevention of premature viscosity during oral use
Maintenance of release-rate specifications
Compatibility with coating and compression
Consistency across different water qualities and agitation conditions
Preservation of capsule or tablet integrity during storage
Reproducible performance at the 0.9 mm needle threshold

A design-around product may avoid this patent but encounter separate patents covering manufacturing steps, coated multiparticulates, opioid-antagonist sequestration, tablet hardness, abuse-deterrent coatings or controlled-release matrices.

How does this patent compare with later abuse-deterrent patent estates?

Issue	U.S. 7,776,314	Later abuse-deterrent estates
Core mechanism	Viscosity-induced gel	May use hardness, gelling, antagonists, aversive agents or matrix resistance
Active ingredient	Broad categories	Often tied to a specific opioid or product
Dosage form	Broad solid oral forms	Frequently product-specific
Key test	10 mL water, 25°C, 0.9 mm needle, visual distinction	Varies by patent and product
Orange Book relevance	Not automatic	Often greater for approved product patents
Current U.S. status	Expired	Depends on individual patent family
Design-around focus	Gel behavior and viscosity	Product-specific structural or functional limitations

The patent is historically important as a broad platform claim, but it should not be used as a proxy for the current freedom-to-operate position of an abuse-deterrent opioid product.

What revenue exposure was associated with this patent?

No direct revenue exposure can be assigned to U.S. Patent 7,776,314 without tying it to a specific approved product, license agreement or enforcement program.

The patent covers numerous active ingredients and dosage forms, but breadth does not establish commercial use. Revenue exposure would require evidence of:

A product practicing the claims
A license or royalty agreement
A patent assertion against a competitor
An Orange Book listing
Sales during the enforceable patent term
A continuing product franchise dependent on the patent

After expiration, the patent has no prospective U.S. exclusivity value. Its residual value is limited to historical damages claims, portfolio analytics and technical know-how that may not be publicly disclosed in the patent.

Key Takeaways

U.S. Patent 7,776,314 is a broad formulation patent covering oral solid dosage forms that form a visually distinguishable, needle-passable gel after aqueous extraction.
Claim 1 is not limited to oxycodone or any other single opioid. It reaches broad classes of abuse-prone active ingredients.
The 10 mL water, 25°C and 0.9 mm needle test is the principal infringement limitation and the most likely point of technical dispute.
Claims 4, 6, 7 and 10 to 12 extend the patent to specific viscosity agents, controlled-release systems, gastric-resistant coatings and multiparticulate products.
The patent is not automatically an Orange Book patent and does not independently create Paragraph IV risk without listing against a particular approved NDA product.
The patent’s ordinary term has expired, and it should not present a current U.S. blocking position in 2025.
Later abuse-deterrent patents may remain relevant even when a product avoids or outlives U.S. Patent 7,776,314.

FAQs

Does U.S. Patent 7,776,314 cover oxycodone products?

It can cover an oxycodone product if the product satisfies every limitation of claim 1 or a dependent claim, including the 5 mg viscosity-agent threshold and the specified gel-extraction behavior. The patent does not claim oxycodone itself.

Can a product avoid the patent by using less than 5 mg of polymer?

Potentially, but only if no other viscosity-increasing agent brings the total within the claimed quantity and the product does not otherwise satisfy the relevant claim. Claims 1 and 9 both contain the 5 mg quantity concept.

Does an abuse-deterrent FDA label prove infringement?

No. FDA abuse-deterrent labeling and patent infringement involve different standards. The product must satisfy the patent’s specific composition and extraction limitations.

Could a liquid-deterrent opioid formulation infringe this patent?

A purely liquid product would generally not satisfy the claimed solid dosage-form limitation. A solid product that becomes liquid or gel-like only after tampering requires a separate claim analysis.

Is a patent license needed for a product launched after expiration?

Not for conduct occurring after the patent has expired, assuming no separate enforceable continuation, divisional, reissue or related patent covers the product. The broader patent family must be checked separately.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/patents/laws/patent-term-adjustment
United States Patent and Trademark Office. (2010). U.S. Patent No. 7,776,314, Abuse-proofed dosage form. https://patents.google.com/patent/US7776314B2
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations, 37th edition. U.S. Department of Health and Human Services.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 27 077	Jun 17, 2002
Germany	102 50 083	Oct 25, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	411007	⤷ Start Trial
Australia	2003237944	⤷ Start Trial
Cyprus	1108682	⤷ Start Trial
Germany	10250083	⤷ Start Trial
Germany	50310649	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,776,314

Summary for Patent: 7,776,314